PAVmed (NASDAQ:PAVM) Cut to Hold at ValuEngine

PAVmed (NASDAQ:PAVM) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, ValuEngine reports.

Separately, Maxim Group set a $8.00 price target on shares of TrovaGene and gave the company a “buy” rating in a research report on Thursday, May 23rd.

PAVM stock traded down $0.01 on Friday, hitting $1.05. 296,600 shares of the company’s stock traded hands, compared to its average volume of 277,235. PAVmed has a 1-year low of $0.86 and a 1-year high of $1.70. The stock’s fifty day moving average is $1.11.

PAVmed (NASDAQ:PAVM) last issued its quarterly earnings results on Tuesday, May 21st. The company reported ($0.09) EPS for the quarter.

In other news, CEO Lishan Aklog purchased 30,000 shares of PAVmed stock in a transaction that occurred on Thursday, May 23rd. The stock was acquired at an average price of $1.10 per share, for a total transaction of $33,000.00. Following the transaction, the chief executive officer now owns 848,413 shares in the company, valued at $933,254.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 34.40% of the stock is currently owned by corporate insiders.

PAVmed Company Profile

PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.

Featured Article: Technical Analysis of Stocks and What It Means

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit